产品编号
1450358
CAS 号
87239-81-4
中文名称
(6R,7R)-1-((异丙氧基羰基)氧基)乙基7-((Z)-2-(2-氨基噻唑-4-基)-2-(甲氧基亚氨基)乙酰氨基)-3-(甲氧基甲基)-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸乙酯 (头孢泊肟酯杂质)
MDL 号
分子量
557.60
存储条件
网页展示纯度为入库指导纯度值,各批次间存在一定差异,实际纯度以收货为准
熔点
111-113 °C
沸点
闪点
旋光
描述
TPSA
180.97
LogP
0.827
H_Acceptors
14
H_Donors
2
Rotatable_Bonds
10
[1]. Ajay Kothadiya, et al. A multicentric, open label, randomised, postmarketing efficacy study comparing multidose of lincomycin hydrochloride capsule 500 mg with multidose cefpodoxime proxetil tablet 200 mg in patients with tonsillitis, sinusitis. J Indian Med Assoc. 2012 Aug;110(8):580-3.
[2]. Amrita Bajaj, et al. Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate. Drug Dev Ind Pharm. 2013 May;39(5):635-45.
[3]. Anil Dubala, et al. Simultaneous quantification of cefpodoxime proxetil and clavulanic acid in human plasma by LC-MS using solid phase extraction with application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 15:921-922:49-55.
[4]. Evren Gundogdu, et al. Comparison of cefpodoxime proxetil release and antimicrobial activity from tablet formulations: complexation with hydroxypropyl-β-cyclodextrin in the presence of water soluble polymer. Drug Dev Ind Pharm. 2012 Jun;38(6):689-96.
[5]. Fahim Khan, et al. Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles. AAPS PharmSciTech. 2010 Sep;11(3):1368-75.
警示图
警示词
Warning
危险申明
H302-H315-H319-H335
警告申明
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
GHS 编码
GHS07
展开更多
现货供应
专业护航
售后无忧
品质保障
无需凑单